The effects of saffron (<i><scp>Crocus sativus</scp> L</i>.) in conjunction with concurrent training on body composition, glycaemic status, and inflammatory markers in obese men with type 2 diabetes mellitus: A randomized double‐blind clinical trial

The researchers tested three interventions against a control group that changed nothing:

**Concurrent training (CT):** A supervised exercise program combining resistance training (weight lifting) and aerobic training (cardio), performed three times per week for 12 weeks. Participants also took a placebo pill (maltodextrin) daily.

**Saffron supplementation (S):** One 100 mg pill of saffron taken daily for 12 weeks, with no exercise program.

**Concurrent training + saffron (CTS):** Both the exercise program and the 100 mg saffron pill daily for 12 weeks.

**Control (CON):** Continued normal lifestyle — no exercise program, no supplement.

The primary outcomes were inflammatory markers: tumour necrosis factor-alpha (TNF-α), high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), interleukin-1β (IL-1β), and interleukin-10 (IL-10, an anti-inflammatory marker). Secondary outcomes included body composition (body weight, BMI, waist-to-hip ratio, body fat percentage, lean body mass) and glycaemic markers (fasting blood glucose, insulin, HOMA-IR, and HbA1c).

**Sample size:** 60 obese men with type 2 diabetes mellitus (T2DM), randomly assigned to four groups of 15 each.

**Age:** 39 ± 5 years (range 30–50).

**Body mass:** 93.9 ± 6 kg.

**BMI:** All >30 kg/m² (obese).

**Diabetes criteria:** HbA1c ≥6.5%, fasting blood glucose ≥126 mg/dL, diagnosed with T2DM for >2 years.

**Medications:** Allowed only oral hypoglycaemic agents (metformin or glibenclamide). Excluded if taking insulin, anticonvulsants, antihypertensives, or lipid-lowering drugs.

**Exclusions:** Hepatic, renal, bone, or cardiovascular disease; severe hypertension; diabetic complications (neuropathy, retinopathy); type 1 diabetes; smoking or alcohol use in the past year; regular physical activity in the past year; saffron allergy.

**Setting:** Tehran, Iran. Recruited from the community.

**Important limitation for generalisation:** Only men were studied. The results may not apply to women, older adults (over 50), or people with more advanced diabetes or on insulin therapy.

**Body composition:** Multi-frequency bioelectrical impedance device (Jawon X-Contact 356, South Korea). This sends a weak electrical current through the body to estimate fat mass, lean mass, and body fat percentage. Test-retest reliability is high (R = 0.95–0.99). Waist and hip circumference were measured with a tape measure for waist-to-hip ratio.

**Inflammatory markers:** Blood samples were collected after an overnight fast. Serum was analysed using commercial enzyme-linked immunosorbent assay (ELISA) kits for TNF-α, hs-CRP, IL-6, IL-1β, and IL-10. Intra-assay coefficients of variation were <8%, inter-assay <10% — meaning the lab measurements were reasonably precise.

**Glycaemic markers:** Fasting plasma glucose (glucose oxidase method), HbA1c (immunoturbidimetry), fasting insulin (ELISA kit). HOMA-IR (homeostatic model assessment for insulin resistance) was calculated from fasting glucose and insulin using a standard formula.

**Timing:** All measurements taken at baseline and after 12 weeks, approximately 48 hours after the last exercise session, at the same time of day (±1 hour), under the same environmental conditions (~20°C, ~55% humidity).

**Study design:** This was a randomised, double-blind, parallel-group clinical trial. "Double-blind" means neither the participants nor the researchers knew who received saffron versus placebo — the pills were identical in appearance. The exercise groups could not be blinded (you know if you're exercising), but the supplement allocation was concealed.

**Randomisation:** Participants were assigned to groups using a digital randomisation tool (www.randomizer.org). This is a standard method to reduce selection bias. However, the paper does not specify whether allocation concealment was maintained (e.g., using sealed opaque envelopes), which is a minor weakness.

**Duration:** 12 weeks of intervention. This is a moderate duration — long enough to see changes in inflammatory markers and HbA1c, but not long enough to assess whether these changes reduce diabetes complications (heart attacks, kidney disease, nerve damage).

**Exercise protocol:** Concurrent training (resistance + aerobic) three times per week. The paper does not provide full details of the exercise prescription (sets, reps, intensity, duration of aerobic sessions) in the abstract, but the full text would specify this. Typically, concurrent training involves ~20–30 minutes of resistance exercises followed by ~20–30 minutes of aerobic activity.

**Statistical approach:** The authors used analysis of variance (ANOVA) to compare changes between groups, with post-hoc tests to identify which groups differed. They also calculated Pearson correlations between changes in body fat percentage and changes in inflammatory markers.

**What this design can prove:**

Cause-and-effect for saffron supplementation (because of randomisation and double-blinding).

The additive effect of combining saffron with exercise (because of the four-group design).

That the changes are due to the interventions, not to placebo effects or natural recovery (because of the control group).

**What this design cannot prove:**

Long-term safety or efficacy beyond 12 weeks.

Whether the effects persist after stopping supplementation or exercise.

Whether the results apply to women, older adults, or people on insulin.

Whether the inflammatory changes translate to fewer clinical events (heart attacks, strokes, amputations) — that would require a much larger, longer trial.

Whether the exercise component alone would have worked without supervision — participants exercised in a lab setting, which may not reflect real-world adherence.

**Major methodological weaknesses:**

1. **Small sample size:** 15 per group. With multiple comparisons (many outcomes), there is a risk of false positives. The authors did not adjust for multiple comparisons (e.g., Bonferroni correction).

2. **Short duration:** 12 weeks is insufficient to assess sustainability or clinical outcomes.

3. **No dietary control:** Participants were asked not to change their diet, but this was self-reported and not verified. Changes in diet could confound results.

4. **Single sex:** Only men. Women have different inflammatory profiles and responses to exercise.

5. **Bioelectrical impedance:** While reliable, this method is less accurate than DEXA scanning for body composition. Changes in hydration can affect readings.

6. **No intention-to-treat analysis mentioned:** If participants dropped out, the analysis method matters. The paper does not state dropout rates in the abstract.

All results are reported as mean changes from baseline to 12 weeks. Negative values indicate reductions.

**Primary outcomes (inflammatory markers):**

**TNF-α (pg/mL):**

- CT (exercise + placebo): ↓4.22

- S (saffron only): ↓1.91

- CTS (exercise + saffron): ↓9.69

- CON (control): no significant change

- *All three interventions significantly decreased TNF-α (P < .05). The CTS group decrease was significantly larger than CT and S alone (P < .05).*

**hs-CRP (ng/mL):**

- CT: ↓0.13

- S: ↓0.10

- CTS: ↓0.32

- *All significant vs. baseline. CTS significantly better than CT and S.*

**IL-6 (pg/mL):**

- CT: ↓6.84

- S: ↓6.36

- CTS: ↓13.55

- *All significant. CTS significantly better.*

**IL-1β (pg/mL):**

- CT: ↓8.85

- S: ↓6.46

- CTS: ↓19.8

- *All significant. CTS significantly better.*

**IL-10 (pg/mL) — anti-inflammatory:**

- CT: ↑1.09

- S: ↑0.53

- CTS: ↑2.27

- *All significant increases. CTS significantly better.*

**Secondary outcomes (glycaemic markers):**

**Fasting blood glucose (mg/dL):**

- CT: ↓6.97

- S: ↓2.45

- CTS: ↓13.86

- *All significant. CTS significantly better.*

**Insulin (mU/L):**

- CT: ↓0.13

- S: ↓0.03

- CTS: ↓0.21

- *All significant. CTS significantly better.*

**HOMA-IR (insulin resistance index):**

- CT: ↓0.12

- S: ↓0.04

- CTS: ↓0.21

- *All significant. CTS significantly better.*

**HbA1c (%):**

- CT: ↓0.17

- S: ↓0.11

- CTS: ↓0.26

- *All significant. CTS significantly better.*

**Body composition:**

The abstract does not report exact numbers for body composition changes, but states that all three interventions significantly improved body weight, BMI, waist-to-hip ratio, and body fat percentage, with CTS being superior.

There was a positive correlation between changes in body fat percentage and changes in inflammatory markers (hs-CRP, IL-6, IL-1β, TNF-α) — meaning people who lost more fat also had greater reductions in inflammation.

Let's translate these numbers into something tangible:

**Inflammation reduction:** The combined intervention (exercise + saffron) reduced TNF-α by about 10 pg/mL. To put this in context, a typical obese person with T2DM might have TNF-α levels around 15–25 pg/mL. A 10 pg/mL drop represents a 40–67% reduction — moving from a high-inflammatory state toward a healthier range. The exercise-only group got about half that effect (~4 pg/mL), and saffron-only got about one-fifth (~2 pg/mL).

**HbA1c reduction:** The combined group dropped HbA1c by 0.26%. For someone starting at 7.5% (a common target for diabetes management), this would bring them to 7.24%. While statistically significant, this is a modest clinical effect. For comparison, metformin typically lowers HbA1c by 1–1.5%. So saffron + exercise is not a replacement for medication, but it could be a useful adjunct.

**Fasting glucose:** A drop of ~14 mg/dL in the combined group. For someone with fasting glucose of 150 mg/dL, this brings them to 136 mg/dL — still above the normal range (<100 mg/dL), but moving in the right direction.

**Insulin resistance (HOMA-IR):** A drop of 0.21 units. Typical HOMA-IR in obese T2DM patients might be 3–5. A 0.21 drop is small — about 5–7% improvement. This suggests the primary benefit is not through dramatic insulin sensitisation, but through reducing inflammation.

**Correlation with fat loss:** The fact that changes in body fat percentage correlated with changes in inflammation suggests that some of the anti-inflammatory effect is mediated by fat loss, not just direct effects of saffron or exercise.

**What the authors acknowledge (from the full text, inferred from abstract):**

The study was short (12 weeks).

Only men were included.

The sample size was relatively small.

Dietary intake was not strictly controlled.

**What a critical reader would note:**

1. **No long-term follow-up:** We don't know if the effects lasted after stopping the intervention. Diabetes management is lifelong.

2. **No clinical outcomes:** The study measured biomarkers, not actual health events. Lower inflammation is good, but does it prevent heart attacks or kidney failure? Unknown.

3. **Dose-response unknown:** Only one dose of saffron (100 mg/day) was tested. Would 200 mg work better? Would 50 mg work as well? Unknown.

4. **Exercise supervision:** Participants exercised in a lab with supervision. Real-world adherence to a 3x/week exercise program is typically much lower. The results may overestimate what a typical person can achieve.

5. **Confounding by weight loss:** The exercise groups likely lost weight. Weight loss itself reduces inflammation. The study cannot separate the direct anti-inflammatory effects of saffron from the indirect effects of weight loss.

6. **Saffron quality and standardisation:** Saffron's active compounds (crocin, safranal, picrocrocin) vary by source, processing, and storage. The study used 100 mg pills, but we don't know the concentration of active compounds. Commercial saffron supplements vary widely in quality.

7. **Drug interactions:** Participants were on metformin or glibenclamide. Saffron may interact with these drugs (e.g., affecting blood sugar or blood pressure). The study did not monitor for adverse interactions systematically.

8. **Funding source:** Funded by Ferdowsi University of Mashhad. No industry funding, which is good. But the authors are from Iran, where saffron is a major agricultural product — there may be cultural or economic interest in positive results.

9. **Multiple comparisons:** With 10+ outcomes measured, the chance of finding at least one "significant" result by chance is high. The authors did not adjust for this.

10. **No placebo for exercise:** The exercise groups knew they were exercising. Some of the benefit could be due to expectation or increased attention from researchers (Hawthorne effect).

For someone running their own n=1 experiment:

### What to test

**Intervention:** 100 mg of saffron (standardised to contain at least 2% crocin) taken daily, combined with a concurrent training program (resistance training + aerobic exercise) three times per week.

**Comparator options:** You could test saffron alone, exercise alone, or both combined. A simple A-B-A design (4 weeks baseline, 12 weeks intervention, 4 weeks washout) would work.

**Dose:** 100 mg/day is the dose used in this study. Saffron is generally safe at this dose, but start with 50 mg for the first week to check for allergic reactions or digestive upset.

### Minimum meaningful duration

**12 weeks minimum.** Inflammatory markers and HbA1c take at least 8–12 weeks to show meaningful changes. Shorter durations may miss the effect.

**For HbA1c specifically:** Since HbA1c reflects average blood sugar over ~3 months, you need at least 12 weeks to see a full effect.

### What to measure

**Primary:** Fasting blood glucose (finger-stick or lab draw), HbA1c (lab draw every 12 weeks).

**Secondary:** Body weight, waist circumference, body fat percentage (if you have a bioelectrical impedance scale — note that accuracy varies).

**Optional but informative:** Fasting insulin (to calculate HOMA-IR), high-sensitivity CRP (a general inflammation marker). These require lab draws.

**Subjective:** Energy levels, mood, joint pain, sleep quality — keep a daily log.

### Key confounds to control for

1. **Diet:** Keep your diet as consistent as possible. Track calories and macronutrients using an app (e.g., MyF